The findings were published online in the American Journal of Respiratory and Critical Care Medicine on June 30, 2011.

A group led by Columbia researcher David J. Lederer followed 129 IPF patients at an academic medical center. They looked at the length of time from the onset of shortness of breath to the first visit to the center. A longer delay was associated with increased risk of death, independent of age, gender, socioeconomic status, lung capacity, disease severity, type of health insurance, or education. The researchers also found no association between the length of delay and the likelihood of the patient's receiving a lung transplant.

IPF leads to respiratory failure and death, usually within three years. It is a relatively rare disease, which afflicts 100,000 to 200,000 Americans, mostly over the age of 50. Characterized by shortness of breath upon exertion, it is often misdiagnosed, especially in people with other ailments.

A delay in making a correct diagnosis can lead to ineffective, or even harmful, treatments. For example, doctors sometimes still treat IPF with steroids, because the disease was originally thought to have an inflammatory component. Now scientists know that steroids are counterproductive. A delay in diagnosis can also delay evaluation for a lung transplant. Although research is underway on potential drug therapies, currently lung transplantation is the only effective treatment.

"The initial symptoms of IPF are subtle, and accurate diagnosis may not be feasible for community-based pulmonologists," explains Lederer, Herbert Irving Assistant Professor of Clinical Medicine and co-director of the New York-Presbyterian Hospital Interstitial Lung Disease Program and Lung Transplant Program.

For that reason, earlier access would be aided by improved methods of early detection. But until then, the recognition, or even suspicion, of IPF should prompt referral to a tertiary care center.

The study's authors are Daniela J Lamas (CUMC), Steven M. Kawut (University of Pennsylvania), Emilia Bagiella (CUMC), Nisha Philip (CUMC), Selim M. Arcasoy (CUMC), and David J. Lederer (CUMC).

The study was supported by the NIH, the Robert Wood Johnson Foundation, and Herbert and Florence Irving.

Note: If no author is given, the source is cited instead.

• Lung Disease
• Lung Cancer
• Cystic Fibrosis
• Diseases and Conditions
• Today's Healthcare
• Asthma

• COPD
• Emphysema
• Bronchitis
• Wheeze
• Transplant rejection
• Delayed puberty